| [1]Hansen T,Kirkpatrick CJ,Walter C,et al.Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis--a paradoxical observation?[J].Virchows Arch,2006,449(4):448-454[2]黄如冰,吴晓林,俞娟.双磷酸盐相关性颌骨坏死12例临床分析[J].中华口腔医学研究杂志:电子版,2012,06(4):31-34[3]Ruggiero SL,Dodson TB,Assael LA,et al.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update[J].Aust Endod J,2009,35(3):119-130[4]Khosla S,Burr D,Cauley J,et al.Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J].J Bone Miner Res,2007,22(10):1479-1491[5]杨万群,黄飚,梁长虹.双磷酸盐相关性颌骨坏死影像学研究进展[J].中国医学影像技术,2010,26(2):381-383[6]Filleul O,Crompot E,Saussez S.Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases[J].J Cancer Res Clin Oncol,2010,136(8):1117-1124[7]Abu-Id MH,Warnke PH,Gottschalk J,et al."Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw[J].J Craniomaxillofac Surg,2008,36(2):95-103[8]Palaska PK,Cartsos V,Zavras AI.Bisphosphonates and time to osteonecrosis development[J].Oncologist,2009,14(11):1154-1166[9]Kyrgidis A,Verrou E.Fatigue in bone: a novel phenomenon attributable to bisphosphonate use[J].Bone,2010,46(2):556-[10]Allen MR,Burr DB.Mandible matrix necrosis in beagle dogs after 3 2008s of daily oral bisphosphonate treatment[J].J Oral Maxillofac Surg,2008,66(5):987-994[11]Bellido T,Plotkin LI.Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability[J].Bone,2011,49(1):50-55[12]Khosla S,Burr D,Cauley J,et al.Oral bisphosphonate-induced osteonecrosis: risk factors,prediction of risk using serum CTX testing,prevention,and treatment[J].J Oral Maxillofac Surg,2008,66(6):1320-1[13]Stresing V,Fournier PG,Bellahcene A,et al.Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase[J].Bone,2011,48(2):259-266[14]Tas F,Duranyildiz D,Oguz H,et al.Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases[J].Med Oncol,2008,25(3):346-349[15]Or C,Cui J,Matsubara J,et al.Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells[J].Br J Ophthalmol,2013,97(8):1074-8[16]Hansen T,Kunkel M,Weber A,et al.Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis[J].J Oral Pathol Med,2006,35(3):155-160[17]Van Poznak C.Osteonecrosis of the jaw and bevacizumab therapy[J].Breast Cancer Res Treat,2010,122(1):189-191[18]Guarneri V,Miles D,Robert N,et al.Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer[J].Breast Cancer Res Treat,2010,122(1):181-188[19]Christodoulou C,Pervena A,Klouvas G,et al.Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone[J].Oncology,2009,76(3):209-211[20]Cornish J,Bava U,Callon KE,et al.Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells[J].Bone,2011,49(4):710-716[21]Landesberg R,Cozin M,Cremers S,et al.Inhibition of oral mucosal cell wound healing by bisphosphonates[J].J Oral Maxillofac Surg,2008,66(5):839-847[22]Moreira MS,Katayama E,Bombana AC,et al.Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous t6a pilot study[J].. Dent Traumatol,2005,21(6):329-335[23]Boff RC,Salum FG,Figueiredo MA,et al.Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws[J].Arch Oral Biol,2014,59(8):790-199[24]Sedghizadeh PP,Kumar SK,Gorur A,et al.Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy[J].J Am Dent Assoc,2009,140(10):1259-1265[25]Di Benedetto A,Gigante I,Colucci S,et al.Periodontal disease: linking the primary inflammation to bone loss[J].Clin Dev Immunol,2013,2013:503754-[26]Nair SP,Meghji S,Wilson M,et al.Bacterially induced bone destruction: mechanisms and misconceptions[J].Infect Immun,1996,64(7):2371-2380[27]Belibasakis GN,Meier A,Guggenheim B,et al.Oral biofilm challenge regulates the RANKL-OPG system in periodontal ligament and dental pulp cells[J].Microb Pathog,2011,50(1):6-11[28]乔光磊,郑水儿,祁伟祥,等.狄诺塞麦与唑来膦酸治疗恶性实体瘤骨转移和多发性骨髓瘤骨相关事件的疗效和安全性的比较:一项Meta分析[J].肿瘤,2013,33(1):48-57[29]Reid IR,Miller PD,Brown JP,et al.Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies[J].J Bone Miner Res,2010,25(10):2256-2265[30]Pazianas M.Osteonecrosis of the jaw and the role of macrophages[J].J Natl Cancer Inst,2011,103(3):232-240[31]Loser K,Mehling A,Loeser S,et al.Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells[J].Nat Med,2006,12(12):1372-1379[32]Toulis KA,Anastasilakis AD.Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab[J].Osteoporos Int,2010,21(11):1963-1964[33]Ziebart T,Koch F,Klein MO,et al.Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw[J].Oral Oncol,2011,47(3):195-201[34]Ruggiero SL,Dodson TB,Fantasia J,et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update[J].J Oral Maxillofac Surg,2014,72(10):1938-1956[35]Grewal VS,Fayans EP.Bisphosphonate-associated osteonecrosisA clinician's reference to patient management[J].. N Y State Dent J,2008,74(1):38-44 |
